IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection
Open Access
- 1 January 2020
- journal article
- other
- Published by Taylor & Francis in OncoImmunology
- Vol. 9 (1) , 1790716
Abstract
IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8+ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.Keywords
Funding Information
- NIH (R01 CA198533 and R01CA201246)
- Breast Cancer Research Foundation
- Spanish Breast Cancer Group
This publication has 10 references indexed in Scilit:
- Radiotherapy Cooperates with IL15 to Induce Antitumor Immune ResponsesCancer Immunology Research, 2020
- Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10Journal for ImmunoTherapy of Cancer, 2020
- Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsClinical Cancer Research, 2018
- The Role of Type 1 Conventional Dendritic Cells in Cancer ImmunityTrends in Cancer, 2018
- A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid TumorsClinical Cancer Research, 2018
- Trial Watch: Immunostimulation with recombinant cytokines for cancer therapyOncoImmunology, 2018
- DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicityNature Communications, 2017
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Interleukin-15 biology and its therapeutic implications in cancerTrends in Pharmacological Sciences, 2012
- Twelve immunotherapy drugs that could cure cancersImmunological Reviews, 2008